![J. Christopher Prue](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
J.
Christopher Prue worked as a Senior Director-Regulatory Affairs at Rani Therapeutics Holdings, Inc. from 2021 to 2023.
Prior to that, he held positions as a Principal at The Upjohn Co., Incara Pharmaceuticals Corp., and Purdue Pharma LP.
He also served as the VP-Regulatory Affairs & Quality Assurance at BioDelivery Sciences International, Inc., Vice President-Regulatory Affairs at AtheroGenics, Inc., Flexion Therapeutics, Inc., and ABIONYX Pharma SA. Mr. Prue completed his undergraduate degree at Purdue University and obtained an MBA from Western Michigan University.
Former positions of J. Christopher Prue
Companies | Position | End |
---|---|---|
RANI THERAPEUTICS HOLDINGS, INC. | General Counsel | 01/09/2023 |
AtheroGenics, Inc.
![]() AtheroGenics, Inc. Pharmaceuticals: MajorHealth Technology AtheroGenics is a pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis, asthma and arthritis. | General Counsel | 14/07/2009 |
BIODELIVERY SCIENCES INTERNATIONAL, INC. | General Counsel | - |
FLEXION THERAPEUTICS, INC. | General Counsel | - |
The Upjohn Co. | Corporate Officer/Principal | - |
Training of J. Christopher Prue
Purdue University | Undergraduate Degree |
Western Michigan University | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
ABIONYX PHARMA | Health Technology |
RANI THERAPEUTICS HOLDINGS, INC. | Health Technology |
Private companies | 6 |
---|---|
AtheroGenics, Inc.
![]() AtheroGenics, Inc. Pharmaceuticals: MajorHealth Technology AtheroGenics is a pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis, asthma and arthritis. | Health Technology |
Purdue Pharma LP
![]() Purdue Pharma LP Pharmaceuticals: MajorHealth Technology Purdue Pharma LP engages in the development and provision of prescription medicines. It offers a portfolio of medical products in categories, including prescription opioids, sleep, laxatives, antiseptics, and dietary supplement. The company was founded by Raymond R. Sackler in 1991 and is headquartered in Stamford, CT. | Health Technology |
Incara Pharmaceuticals Corp. | Health Technology |
The Upjohn Co. | Health Technology |
Flexion Therapeutics, Inc.
![]() Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. | Health Technology |
BioDelivery Sciences International, Inc.
![]() BioDelivery Sciences International, Inc. Pharmaceuticals: MajorHealth Technology BioDelivery Sciences International, Inc. operates as a pharmaceutical company engaged in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. Its products include Symproic and Belbuca. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC. | Health Technology |
- Stock Market
- Insiders
- J. Christopher Prue